ArticleInfectious agents and cancer2025
Serum level of soluble Interleukin-2 receptor among human papilloma virus infected female patients.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progression from infection with human papillomavirus (HPV) to cervical cancer in some women is thought to involve a permissive host environment, one in which immune response is mobilized in an inappropriate manner. Interleukin-2 (IL-2) is one of the most studied cytokines driving T-cell proliferation and survival. Soluble Interleukin-2 receptor (sIL2R) was found to play an immunoregulatory role and is detected in the serum of healthy individuals but increases in association with certain types of neoplasms. The aim of the current study was to assess the serum level of sIL2R in HPV infected female patients with genital warts compared to healthy control women and to correlate the results with cervical cytology (pap smear) results to determine the utility of measuring the serum sIL2R levels in screening of precancerous changes in cervix. The study was conducted on 90 Egyptian female patients with genital warts and 90 apparently healthy controls. Cervical brush samples were taken for both conventional Pap cytology and detection of HPV-DNA. Serum levels of sIL2R were measured by enzyme-linked immunosorbent assay (ELISA). Patients were divided into two groups according to the result of Pap smear: group 1 with Low-grade squamous intraepithelial lesion (LSIL) having flat condyloma on cervix and group 2 with normal pap smear having condyloma accuminata lesions. Serum sIL2R levels of HPV infected patients showed a statistically significant higher median when compared to controls (p value < 0.0001). Also, group 1 showed a statistically significant higher median compared to group 2 regarding sIL2R levels (p value < 0.0001). sIL2R was found to be perfect and reliable in differentiation between group 1 and group 2. Also, it may be useful to use serum sIL2R level for screening of HPV infections and cervical cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.